Insider · CIK 0001326228
Zhengbin Yao
Files at ALMS (ALUMIS INC.), AVBP (ArriVent BioPharma, Inc.). First filing -, latest -.
Zhengbin Yao files SEC Form 4 as CEO, president and director at ALMS (ALUMIS INC.), and also at AVBP (ArriVent BioPharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Zhengbin Yao has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | AVBP ArriVent BioPharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +550,000 | $0.00 | $0 | 550,000 | Feb 4, 2026 |
| Jul 30, 2025 | ALMS ALUMIS INC. | AGrant or award Stock Option (Right to Buy)derivative | +49,800 | $0.00 | $0 | 49,800 | Aug 1, 2025 |
| Feb 3, 2025 | AVBP ArriVent BioPharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +380,000 | $0.00 | $0 | 380,000 | Feb 14, 2025 |
Questions about Zhengbin Yao
Answered from the filings on this page, as of the latest one.
Is Zhengbin Yao buying or selling?
Zhengbin Yao has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Zhengbin Yao's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Zhengbin Yao has 0.
Where does Zhengbin Yao file Form 4?
Zhengbin Yao has filed Form 4 at ALMS (ALUMIS INC.); AVBP (ArriVent BioPharma, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.